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Abstract
Background: Colorectal cancer is the fourth most commonly diagnosed cancer in the United States. Approximately
3–10% of the population has an increased risk for colorectal cancer due to family history and warrants more frequent
or intensive screening. Yet, < 50% of that high-risk population receives guideline-concordant care. Systematic collection
of family health history and decision support may improve guideline-concordant screening for patients at increased
risk of colorectal cancer. We seek to test the effectiveness of a web-based, systematic family health history collection
tool and decision support platform (MeTree) to improve risk assessment and appropriate management of colorectal
cancer risk among patients in the Department of Veterans Affairs primary care practices.
Methods: In this ongoing randomized controlled trial, primary care providers at the Durham Veterans Affairs Health Care
System and the Madison VA Medical Center are randomized to immediate intervention or wait-list control. Veterans are
eligible if assigned to enrolled providers, have an upcoming primary care appointment, and have no conditions that
would place them at increased risk for colorectal cancer (such as personal history, adenomatous polyps, or inflammatory
bowel disease). Those with a recent lower endoscopy (e.g. colonoscopy, sigmoidoscopy) are excluded. Immediate
intervention patients put their family health history information into a web-based platform, MeTree, which provides both
patient- and provider-facing decision support reports. Wait-list control patients access MeTree 12months post-consent.
The primary outcome is the risk-concordant colorectal cancer screening referral rate obtained via chart review. Secondary
outcomes include patient completion of risk management recommendations (e.g. colonoscopy) and referral for genetic
consultation. We will also conduct an economic analysis and an assessment of providers’ experience with MeTree clinical
decision support recommendations to inform future implementation efforts if the intervention is found to be effective.
Discussion: This trial will assess the feasibility and effectiveness of patient-collected family health history linked to decision
support to promote risk-appropriate screening in a large healthcare system such as the Department of Veterans Affairs.
Trial registration: ClinicalTrials.gov, NCT02247336. Registered on 25 September 2014.
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Background
Colorectal cancer (CRC) is the fourth most commonly di-
agnosed cancer in the United States, with 140,788 new
cases and 52,396 deaths in 2015 [1]. Screening by several
modalities has been shown to reduce death from CRC in
average-risk individuals [2–7] and is recommended by
several national organizations [8]. CRC screening via col-
onoscopy or stool testing is recommended for average-
risk individuals beginning at the age of 45 years by the
American Cancer Society [9] and beginning at 50 years by
the United States Preventive Services Task Force [10] and
a Multi-society Task Force [8]. However, different screen-
ing modalities and/or frequencies are recommended for
patients above population-level risk (hereafter referred to
as increased risk), such as those with a personal or family
history of colorectal neoplasia or adenomatous polyps [8].
Risk assessment using family health history (FHH) per-
mits tailoring of CRC screening to an individual’s risk
level. While collection of FHH is incorporated into mul-
tiple clinical guidelines [11, 12], it is rarely used in clinical
practice as part of a standardized risk assessment [13].
Challenges to FHH use in clinical practice include phys-
ician time constraints during office visits, lack of provider
awareness of FHH collection standards, failure of the
medical record to support adequate collection and docu-
mentation of FHH collection, and provider lack of confi-
dence in identifying patients at increased risk for CRC
[14–16]. Subsequently, although 3–10% of the United
States population [17] is thought to be at increased risk
for CRC and, thus, meets criteria for more intensive
screening and management, < 50% receive this recom-
mended care [18–20].
Systematic FHH collection and provision of clinical de-
cision support (CDS) can improve accuracy of identifica-
tion and appropriate prevention management of patients
at increased risk for disease. For example, Qureshi et al.
found that, compared to usual care, systematic FHH col-
lection identified previously undetected primary care pa-
tients who were at increased risk for cardiovascular
disease (4.8% vs 0.3%) [21]. Systematic FHH collection can
also improve appropriate use of strategies for increased-
risk management. Orlando et al. found that the use of a
web-based FHH risk assessment tool increased the pro-
portion of increased-risk management strategies being
delivered appropriately to increased risk patients from
10.5% to 71.8% [22]. Similarly, Scheuner et al. found that a
cancer family history toolkit administered in primary care
practices increased family history cancer documentation
and increased guideline-concordant referral for genetic
consultation more than twofold [23].
Integrated health systems, such as the Veterans Admin-
istration (VA), can benefit from systematic approaches to
FHH collection as they often internally refer patients for
procedures and counseling indicated by patient risk.
Currently, the VA does not have a system-wide approach
to the routine collection and documentation of FHH in
the medical record. This lack of systematic documentation
can result in poor FHH documentation. For example, at
one VA healthcare system, the documentation of FHH for
any cancer was 26.6% of patients seen [23]. Another study
of 500 consecutive patients at a VA hospital revealed that
7% of fecal occult blood test orders by primary care pro-
viders (PCPs) were inappropriate and should have been
referred for colonoscopy instead due to a personal or
FHH that increased risk of CRC [24]. A standardized FHH
collection tool supported by decision support for patients
and providers could provide needed structure to improve
risk-appropriate CRC management [23].
To address the pressing clinical need for improved
risk-identification and risk-appropriate CRC screening,
we are conducting a cluster randomized controlled trial
(RCT) to evaluate the feasibility and effectiveness of
implementing a web-based, systematic FHH collection
and decision support platform (MeTree) [25] in VA pri-
mary care practices. We will evaluate the effect of the
intervention on PCPs’ workflow and health economic
outcomes to inform eventual implementation more
broadly. To that end, our primary aims are: (1) to deter-
mine whether FHH collection via MeTree improves identi-
fication of patients at increased risk for CRC; and (2) to
evaluate whether patient and provider decision support im-
proves risk-appropriate PCP referrals for, and patient up-
take of, CRC screening/surveillance and referral for genetic
counseling. Our secondary aims are: (1) to assess experi-
ence with clinical decision support reports and effects on
primary care provider workflow via qualitative interviews;
and (2) to conduct budget-impact analyses of implementing
FHH collection and decision support in the VA.
Methods
Study setting and design
We are conducting this RCT at two sites: the Durham VA
Health Care System in Durham, NC, including three asso-
ciated primary care clinics, and the William S. Middleton
Memorial Veterans Hospital in Madison, WI. All enrolled
patients are veterans receiving care at one of these medical
facilities. Institutional review boards at the Durham VA
Health Care System and the University of Wisconsin-
Madison (the institutional review board of record for the
Madison VA hospital) approved this study.
This study is a two-arm, cluster-randomized, type I hy-
brid implementation-effectiveness trial that aims to test the
effectiveness of a clinical intervention (i.e. family history risk
assessment with decision support documents) while obtain-
ing data to inform potential future implementation [26].
Enrolled PCPs are randomized to have their patients
complete MeTree either upon enrollment (immediate arm)
or 12months later (wait-list control arm). PCP
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randomization is stratified by site (Durham vs Madison)
and provider type (physician versus advanced practice pro-
vider [physician assistant or nurse practitioner]) in case
there are differences in extent of knowledge about FHH in
guideline-concordant care or use of the information in clin-
ical practice. We aim to sub-stratify by age within provider
sub-groups (40–49 years vs 50–64 years) to address the po-
tential for intervention effects that differ across age groups
given that population-based screening begins at the age of
50 years. We chose a 12-month wait-list control arm as the
comparator group to ensure that all patients receive the
benefit of risk-appropriate screening. The primary outcome
for this study is risk-appropriate CRC screening referral at
12months. Secondary outcomes include patient comple-
tion of CRC screening referral and risk-appropriate genetic
consultation, economic outcomes, and barriers and facilita-
tors to intervention use (see Table 1 for additional details
of study activities by time point). This trial is registered at
clinicaltrials.gov (NCT02247336) (see Additional file 1 for
additional trial registration items). Checklist for standard
protocol items are listed in Additional file 2.
Study population and recruitment
Primary care provider recruitment and randomization
Provider inclusion/exclusion criteria are listed in Table 2.
To recruit providers, we attend staff meetings to introduce
the study; we do not provide education regarding FHH or
CRC during these meetings. PCPs can consent to participate
at the meeting or later via email. We use a rolling
recruitment strategy to capture any newly hired providers
who wish to participate. Providers enroll via email to the site
PI in Durham (KG) and a study team member in Madison.
The study coordinator (ES) enters consented providers into
a study database for randomization assignment.
Randomization is at the provider level to avoid contamin-
ation by a provider having patients in both study arms (see
Fig. 1). Using SAS version 9.4 software, the study statistician
developed a randomization scheme for allocating providers
to the immediate or wait-list control arm and within stratifi-
cation groups of provider type (advanced practice provider
[nurse practitioner or physician assistant] vs physician). The
resulting randomization assignment list was imported into
the study’s tracking database. As providers consent to par-
ticipate, they are assigned to the arm that was randomly as-
sociated with the next vacant slot on the randomization list
for their provider type. Within the stratification groups, pro-
viders are allocated in block sizes (block size is unknown to
everyone but study statisticians).
Patient recruitment
Patient eligibility is determined using a combination of elec-
tronic medical record (EMR) data and telephone screening
Table 1 Study activities by time point (SPIRIT Table)
Study time point
Provider recruitment
T− 2
Patient screening
T− 1
Baseline
T0
0–30 days post-baseline
T1
12 months post-baseline
T2
Provider recruitment
Contact eligible providers X
Info sessions at clinic X
Informed Consent X
Randomization X
Patient recruitment
Mailing recruitment letters X
Telephone screen X
Informed consent X
Randomization revealed X
Intervention (MeTree)
Immediate arm X
Delayed arm X
Assessments
Baseline survey X
Exit survey – immediate X
Exit survey – delayed X
12-month survey (all) X
Chart abstraction (all) X
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(see Table 2). We identify patients of enrolled PCPs with an
upcoming primary care appointment (at least six weeks out)
using EMR appointment schedules. We mail patients a re-
cruitment letter and informational brochure about MeTree.
Patients may opt out of the study by calling a toll-free num-
ber; otherwise, study personnel may contact potential
patient participants by telephone to explain the study and
assess interest. During the telephone contact, study staff
verify eligibility and willing patients provide verbal con-
sent (see Additional file 3 for informed consent language).
During the recruitment call, consented patients
complete a baseline telephone survey (see Table 3) about
health screening history and a computer proficiency
assessment [28]. After completing the survey, we inform
patients of their randomization assignment, determined
by whether their PCP was randomized to the immediate
versus wait-list control arm. Once randomized, patients
remain in their original treatment assignment arm even
if they change providers. To be enrolled in the study and
thus included in analyses, patients must complete
MeTree to determine their CRC risk level. We expect a
lower MeTree completion rate for patients in the wait-
list control arm compared to the immediate arm because
of the planned 12-month delay between baseline survey
and MeTree assessment in the control arm. Therefore,
we plan to enroll approximately 100 more patients in
the control arm than in the immediate arm to enable us
to meet our targeted sample size of n = 250 completed
MeTree assessments in each arm (see the “Statistical
power and sample size” section).
Blinding
Enrolled providers are not informed of their study arm at
enrollment. However, we do alert them that their patients
will start receiving the intervention either shortly after en-
rollment or 12months later. Patient receive their treatment
arm assignment immediately after completing the baseline
survey. Blinding of outcome assessors cannot be completely
ensured as described below under “Measures,” but attempts
are made to preserve blinding as much as possible.
Study procedures
Immediate arm
A few weeks before beginning patient enrollment, we
provide PCPs randomized to the immediate group with
details about the study (e.g. where to find the decision
support document in the EMR) via a link to a video of a
slide-based presentation with accompanying voice-over.
We also provide them with a copy of the slide set. We
ask providers not discuss the decision support docu-
ments, process, or experience with other clinicians.
Study team members send PCPs randomized to the
wait-list control group an email with this same informa-
tion 12months later. PCPs are responsible for ordering
recommended tests as they deem clinically appropriate
Table 2 Eligibility criteria and method of ascertainment
Criteria Method
Primary care provider
Inclusion Physician, nurse practitioner, or physician assistant Administrative & Phone screen
Working in one of the targeted primary care clinics Administrative & Phone screen
At least one half-day of primary care clinic per week Administrative & Phone screen
Patient panel size large enough to enroll 12–13 patients Administrative & Phone screen
Patient participant
Inclusion Assigned to one of the enrolled PCPs Administrative & Phone screen
At least one primary care appointment in
the 18 months before enrollment
Administrative & Phone screen
Upcoming PCP appointment with assigned PCP Administrative & Phone screen
Aged 40–64 years Administrative & Phone screen
No previous history of CRC (V10.05, V10.06, ICD-9153, 154),
inflammatory bowel disease (555.0, 555.1, 555.2, 555.9, 556.0),
or adenomatous polyps (indicated in pathology report)
Administrative & Phone screen
Exclusion Endoscopy within the previous 3 years Administrative & Phone screen
Plans to relocate or leave the VA healthcare system in the next 12 months Phone Screen
More than 2 errors on a validated 6-item screener for cognitive impairment Phone screen
Non-English speaking Phone screen
No knowledge of FHH of first- and second-degree predecessor relatives, even if adopted Phone screen
Concurrent enrollment in a competing research study (related to colon cancer) Phone screen
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Fig. 1 Study flow
Table 3 Survey measures by study time point
Measures Baseline survey 12-month survey Exit survey
Demographics X
Quality of life (Euro-QoL [27]) X X
Personal history of genetic testing X X
Personal history of health screeninga X X
Computer proficiency (CPQ-12 [28]) X
Experience with MeTree X
Topics discussed with PCP X
aCRC, breast cancer, ovarian cancer, lung cancer, diabetes mellitus, and cardiovascular disease
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and per patient agreement after discussion of personal
preferences and medical co-morbidities.
Patients assigned to PCPs who are randomized to the
immediate arm are offered the choice of completing
MeTree online on their own or at the hospital with
study personnel. We provide the username and pass-
word for MeTree to patients by mail, text message, or
the Veterans Health Administration’s Secure Messaging
system (MyHealtheVet), or multiple modes, depending
on patient preference. We encourage patients to
complete MeTree before their upcoming primary care
visit with reminder phone calls, text messages, or secure
email messages sent up to twice per week. For patients
who need assistance, they may choose to complete
MeTree in-person by meeting with study personnel be-
fore their scheduled appointment or at another conveni-
ent time. The number of patients requiring assistance is
tracked and recorded in a study database. For patients
who complete MeTree on their own, we place the
provider-facing report into the patient’s EMR and alert
the PCP. Patients who complete MeTree in-person re-
ceive a paper copy of the patient-facing decision support
documents to share with their PCP at their appointment
and the provider-facing decision support document is
uploaded into the EMR. Patients in the immediate arm
complete an exit survey shortly after completing MeTree
(e.g. experience with program and topics discussed with
their PCP) and a follow-up survey 12months later (e.g.
updated assessment of personal health screenings and
genetic testing) (see Table 3). After MeTree is completed
and a clinical decision support document rendered, pa-
tients may still enter new information into the system
that might develop at a later time; however, any changes
in their report would not be transmitted.
Wait-list control arm
At 10–11 months after consent of the first several pa-
tients, we contact wait-list PCPs to provide the same
education (i.e. informational email and slide set) that
was provided to PCPs in the immediate arm. When we
disclose the randomization assignment to patients in the
wait-list control arm, we inform them that we will con-
tact them 12months post-consent to complete MeTree.
We advise these patients that there is little risk associ-
ated with waiting, as CRC takes 7–10 years to develop.
During the 12-month follow-up period, neither wait-list
control patients nor their providers receive further con-
tact from study personnel.
Ten months after each wait-list control patient pro-
vides consent, we mail a reminder letter informing them
about the process to complete MeTree. We also tele-
phone these patients to assess their preference for mode
of completion using the aforementioned procedures. We
follow the same procedures for uploading the PCP
decision support document requiring electronic signa-
ture from the provider. Wait-list control arm patients
complete their exit survey and their 12-month survey at
the same time (see Table 3).
All patients receive a small financial compensation
after completion of MeTree (baseline or 12 months later,
depending on study arm).
Description of MeTree
MeTree is a patient-facing, web-based, FHH collection
and clinical decision support platform developed in 2004
[25]. It was designed to include a patient-friendly, inter-
active interface for entering FHH. MeTree’s algorithms
are based on current clinical guidelines used by PCPs
(e.g. United States Preventive Services Task Force, Na-
tional Comprehensive Cancer Network). The current
version collects information on personal and FHH for 90
conditions and provides evidence-based, guideline-
concordant, patient-specific recommendations for
screening on 30 conditions [29]. Additional description
of MeTree development, validation, and acceptability
has been published [25, 29, 30].
We provide patients with a worksheet to assist them
in collecting FHH from their family members before log-
ging into MeTree. The worksheet is downloadable from
the MeTree website but is also mailed to patients, de-
pending on timing and preference. The worksheet ex-
plains the importance of FHH and guides patients to
collect pertinent information from family members. Al-
though this study focuses on CRC as the disease context
for the primary outcome, we ask patients to enter their
personal and FHH for all diseases included in MeTree.
The MeTree decision support document includes deci-
sion support for any of the 30 conditions for which the
patient may be at increased risk.
To complete MeTree, patients enter their personal
and family health history directly into the web-based
platform following easy-to-read prompts. Then, the
MeTree program analyzes the data using existing guide-
lines to generate a report for the patient. MeTree also
generates a provider report with citations for relevant
supporting guidelines that is uploaded in the EMR for
provider review.
Measures
We are collecting patient demographics and self-
reported cancer screening at baseline and 12months
after consent (see Table 3). We also assess patients’ ex-
periences using MeTree during a brief exit survey that is
administered within one month of MeTree completion
for both arms. We review the EMR and administrative
data to assess the remaining outcomes. Study personnel
at both sites conduct chart reviews. Blinding of outcome
assessors cannot be ensured because the MeTree
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decision support document for PCPs is part of the pa-
tient’s EMR. However, we attempt to maintain blinding
to the extent possible by having study personnel
complete chart abstractions without accessing the study
database so that they are not directly able to see the
randomization status of each patient. To decrease the
risk of ascertainment bias and to standardize the ab-
straction process, a detailed record abstraction protocol
with data dictionary is created and training was con-
ducted by a gastroenterologist on the study team (DF).
Outcomes
The primary outcome for this study is a binary outcome
of whether risk-appropriate CRC screening referral oc-
curred during the 12 months after consent. In order to
measure this outcome, we need to know if a patient is at
increased risk for CRC and the risk-appropriate recom-
mendations for screening for that individual (i.e. the out-
comes of our first aim). Thus, the primary outcome
assessment follows completion of our first aim. Patients’
EMRs are reviewed for CRC-related screening referrals
in the 15 months subsequent to consent. We are includ-
ing an extra three months to capture any delayed uptake
in recommended referrals. Specifically, clinical notes and
consults are reviewed to identify referrals. For patients
in both arms, risk-appropriate referral is based on the
CRC risk level determined by the algorithm and recom-
mendations from the MeTree program. Note that for pa-
tients determined to be at average risk for CRC by the
MeTree program, a risk-appropriate referral may be no
referral for CRC screening or surveillance.
Secondary outcomes are binary outcomes for patient
completion and uptake of the CRC screening or surveil-
lance referral, and risk-appropriate referral to genetic
consultation over the 12-month follow-up period. We
are examining patient uptake of CRC screening/surveil-
lance referral for the subset of patients who received a
risk-appropriate CRC screening or surveillance referral;
patients who have no risk-appropriate referrals are not
included in this analysis. A referral is identified by hav-
ing an order in the record. Referral for CRC screening is
identified as “recommended/ordered” and “completed.”
“Recommended/ordered” is defined as the placement of
an order for CRC screening or mention of such in the
medical record, but the ordered screening is not com-
pleted. “Completed” refers to an order that was both
placed and completed. We also look for the referral, ac-
tual order, and completion of risk-appropriate genetic
consultation. As patient history can change over a 12-
month period, when collecting self-reported screening
history during the 12-month phone call, we ask patients
if they have had any new relevant FHH diagnoses.
A secondary outcome for the study is baseline risk
categorization for CRC in the EMR before study
enrollment. We audit the EMR of all patients enrolled in
the study to determine whether, at baseline, they
were identified as being at increased risk for CRC based
on an observation of either: (1) a diagnosis of being at in-
creased risk for CRC (diagnosis code: V16.0); or (2) docu-
mentation of being at increased risk for CRC in the EMR.
Study staff review progress notes or documentation of
FHH of CRC, including the relationship and age at diag-
nosis or explicit statement of no FHH of CRC. This is ac-
complished with a text search. Initially, we are validating
our search terms in a subset of 25 patients. If necessary,
the terms will be adjusted to accommodate those found in
the initial 25 patients and validation will be repeated on
an additional 25 patients. To decrease the risk of ascer-
tainment bias and to standardize the abstraction, a de-
tailed record abstraction protocol with data dictionary was
created and training will be conducted.
To complete follow-up and conduct both exit and 12-
month surveys, we will attempt to reach patients by
phone until the end of the survey window (one month
after MeTree for the exit survey and 58 weeks after con-
sent for the 12-month survey). If we cannot reach pa-
tients by phone for these surveys, we will still complete
their chart review as described above.
Data management
Our primary and secondary outcome measures are col-
lected in an electronic chart abstraction survey using
data entry/management software DatStat Illume (version
5.1 before 29 January 2019 and version 6.1 subse-
quently). Baseline and 12-month follow-up survey data
are also captured electronically in Illume. We developed
a centralized tool for capturing data across study sites
electronically using a custom patient tracking application
and Illume. The tracking application and Illume are
housed on a secure database server behind the VA fire-
wall with access limited to key personnel. Data entered
by patients into the MeTree online tool are stored on a
secure Duke website that meets VA security standards.
Throughout enrollment and data collection, we monitor
data quality, accuracy, and timeliness.
Analyses
Primary aims
Aim 1 is to determine whether FHH collection via
MeTree improves identification of patients at increased
risk for CRC by comparing rates of increased risk identi-
fication in the medical record before study enrollment
(baseline risk) to rates of high-risk identification by
MeTree. As patients in both arms use MeTree for risk
assessment, the design for this aim is a pre-/post-com-
parison within patient. We will test whether MeTree risk
is higher than baseline risk using a McNemar’s test ad-
justed for clustering of patients within PCP. Note that
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the outcome for this aim is used in the primary outcome
analysis.
Aim 2, the primary effectiveness aim, is to evaluate
whether providing decision support to patients and PCPs
improves risk-appropriate PCP referrals for CRC screen-
ing/surveillance and, secondarily, whether it improves
patient uptake of CRC screening/surveillance and risk-
appropriate referrals to genetic counseling. For the
referral and uptake outcomes we will use generalized
estimating equations (GEE) models to account for clus-
tering of patients within PCP [31]. Because the primary
and secondary outcomes are binary, we will use a GEE
with a logit link function and an exchangeable correl-
ation structure for each outcome. We will report 95%
confidence intervals for the parameter estimates and p
values from Wald t-tests with bias-corrected empirical
sandwich estimators to maintain type I error control due
to small numbers of clusters [32, 33]. Empirical standard
errors are robust to misspecifications of the correlation
structure.
The primary analyses for this cluster RCT will be con-
ducted on an intent-to-treat basis. The main conclusions
drawn from this trial will be based on the pre-specified
primary and secondary hypotheses outlined previously
and will be tested with two-sided p values at the stand-
ard level of 0.05 with effect size estimates and associated
95% confidence intervals reported. For both primary and
secondary outcomes, stratification variables (provider
type and patient age categorization) will be included in
GEE models. Given that the outcomes are determined
based on EMR review over a 12-month period, there
should be very little missing data. The most likely sce-
narios to explain missing data are that a patient dies
during the study or leaves the VA system before comple-
tion of the 12-month follow-up period.
We will conduct descriptive analyses of data acquired
through the baseline, exit, and 12-month follow up sur-
veys. Statistical analyses are performed using SAS for
Windows (Version 9.4: SAS Institute, Cary, NC, USA)
and R (http://www.R-project.org).
Statistical power and sample size The sample size esti-
mate of n = 250 patients with a completed MeTree as-
sessment per arm (total n = 500) with 40 providers (20
in each arm) is based on 80% power, a type-I error rate
of 5%, 4% loss to follow-up, and Z-test for the difference
of two proportions adjusted for provider clustering. For
the difference-in-proportions sample size calculation, we
assumed a risk-appropriate screening referral rate for
the wait-list control arm in the range of 60–70% [34].
The sample size for difference in proportions was ad-
justed by an intraclass correlation coefficient (ICC), a
measure of “relatedness” of patients within a PCP to ac-
count for patient clustering within provider; we used an
ICC of 0.02 [35, 36]. PASS 2008 [37] was used for all
sample size calculations. Table 4 gives the estimated dif-
ference in proportions under the above stated assump-
tions that we can detect for the range of baseline referral
rates in the wait-list control arm adjusted for clustering
of providers and assuming a loss to follow-up of 4%.
For the secondary outcome, uptake of risk-appropriate
CRC screening, our sample size is smaller as this out-
come is only available for veterans that were referred for
a CRC screening/surveillance test. Based on a hypothe-
sized CRC screening/surveillance referral rate of 60% in
the control arm and 73% in the immediate arm, the ef-
fective sample size after applying the 4% loss to follow-
up is approximately 140 in the control arm and 180 in
the immediate arm. With this effective sample size, a
type-I error rate of 5%, and an ICC of 0.02, we can de-
tect a difference of 15.6% in uptake of CRC screening
test rates between arms with 80% power.
Secondary aims
Economic/cost analyses We will also conduct a budget
impact analysis (BIA) of the MeTree system to estimate
the real-world financial implications of such an interven-
tion. This analysis is conducted from the perspective of
the VA healthcare system. Therefore, costs incurred by
patients, such as travel or work absence to receive
healthcare services, are not included. We will convert all
cost figures to current dollars using the Bureau of Labor
Statistics Consumer Price Index Calculator (https://data.
bls.gov/cgi-bin/cpicalc.pl). Given that a horizon of 1–5
years is common for BIAs, we will use a three-year time
horizon [38].
Our analyses include costs associated with the follow-
ing elements: the FHH collection intervention; screening
for CRC; genetic counseling; and genetic testing. These
cost elements will be generated prospectively for both
the immediate and wait-list control groups.
Table 4 Estimated differences in CRC screening referral rates that can be detected between arms for different baseline screen
referral rates with 80% power
Sample size (per arm) Baseline CRC screening referral rate for control arm (%) Estimated difference in CRC screening referral between arms (%)
250 60 13.2
250 65 12.7
250 70 12.0
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To derive intervention cost, we take an implementation
perspective. The cost of the intervention will include cost
of the computer required for MeTree use in clinic (if pa-
tient is met in clinic before appointment), providing the
decision support documents, and the labor cost of provid-
ing assistance to patients to use MeTree and generate
notes in the EMR for each patient’s PCP. We will account
for the cost of training the coordinator to facilitate patient
use of MeTree and entering notes in the EMR and of edu-
cating PCPs on the intervention. We will collect a sample
of time required to perform each of these tasks and apply-
ing appropriate wage and fringe benefit rates to calculate
labor cost. Collecting FHH through MeTree may be time-
consuming and lead to longer patient visits. While we do
not have a provider survey, we are conducting qualitative
interviews with PCPs. During these interviews, we ask
PCPs to quantify the impact of the MeTree tool on the
length of their clinic visits. If PCPs report an increase or
decrease in time spent with patients, then we will apply a
wage-per-minute cost to the time difference to derive an
incremental visit time cost. Study-related costs, such as
the study coordinator’s time to consent and randomize
patients, are not included. Development costs, such as de-
signing MeTree and decision support materials, are
treated as a one-time “sunk cost” that has already been in-
curred and are not included in our calculations.
The intervention may differentially impact utilization
of healthcare services. We will derive screening costs of
fecal occult blood test, flexible sigmoidoscopy, or colon-
oscopy from the VA’s Managerial Cost Accounting out-
patient and inpatient extracts datasets. We will collect a
sample of times required to provide CRC genetic coun-
seling and wage and fringe benefit rate for genetic coun-
selors to estimate the cost of providing CRC genetic
counseling. For patients who receive genetic testing, we
will apply the prevailing market rate for a genetic test at
study conclusion to the analysis. Although intervention
and screening costs are likely to be higher in the imme-
diate arm, at least some of this cost may be mitigated by
cost savings from CRC cases being averted. We will use
estimates of the rate and cost of CRC from the literature
to incorporate this cost component.
The net budget impact of the intervention is the differ-
ence in total costs incurred by patients in the immediate
and wait-list control arms. We will also build on our
BIA to conduct a cost-consequence analysis. The conse-
quences of clinical interest are the additional number of
appropriate referrals for genetic counseling, genetic test-
ing, and additional cases of CRC detected due to the
intervention. We will use these cost and consequence es-
timates from our sample to extrapolate what the budget
impact and additional cases of CRC detected would be if
the intervention were to be available for the entire VA
healthcare system and veteran population.
Qualitative interviews with providers Our study also
includes a secondary aim to assess context for implemen-
tation. This aim employs qualitative methods to evaluate
PCPs’ experiences using MeTree and how it affects their
workflow. This information will provide important con-
text to help interpret quantitative findings on uptake and
effectiveness and additionally consider issues around oper-
ability and feasibility for future wide scale adoption and
implementation. We aim to conduct 20-min semi-
structured interviews by phone with 4–5 PCPs at each
site. Guided by Weiner’s organizational model of imple-
mentation readiness [27, 39–41], the interviewer asks par-
ticipating providers about their use of FHH in clinical
decision-making (i.e. innovation-values fit), how they be-
came aware of whether their patients completed MeTree,
how they used or did not use the MeTree recommenda-
tions, how their patients reacted to the recommendations
(i.e. implementation effectiveness), how MeTree affected
their workflow and the time required to act on the recom-
mendations, and any barriers to implementing MeTree
recommendations (i.e. innovation-task fit). Interviews are
audio-recorded and transcribed. Data will be analyzed
using conventional content analysis, in which codes, or
descriptive labels, will be attached to relevant passages of
text in transcripts [42]. A team of two qualitative analysts
code data, first working independently, and then meeting
to evaluate consistency. Differences will be resolved by
discussion and consensus. As is standard practice, analysis
will be iterative (i.e. we code and discuss an initial tran-
script before moving to a second one with an updated
coding scheme). The final coding scheme will be applied
to all transcripts, recoding transcripts that were coded
with earlier versions of the codebook as necessary. Ana-
lysts will identify themes by reviewing coded data for pat-
terns about facilitators and barriers to inform future
implementation [43].
Monitoring and ethics This study does not have a data
monitoring committee as no medical treatment is being
provided as part of the intervention and all patients will
eventually receive the intervention. There are no signifi-
cant anticipated harms from this intervention; however,
we track adverse events according to IRB regulations.
Adverse events are not assessed systematically; they are
recorded if we become aware of them (e.g. a patient
mentions an illness during a conversation with a study
team member). Significant protocol modifications are
enacted only after IRB approval and are updated in trial
registration and described in subsequent manuscripts.
Discussion
The systematic collection of a comprehensive FHH
combined with readily available, guideline-concordant
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decision support is crucial to promote timely, patient-
centered risk assessment and management. We are
conducting a trial to test the effectiveness of such an
approach in the VA while gathering information that
will inform future implementation.
Our study design offers distinct strengths. First, previ-
ous studies of MeTree have not included a control
group, precluding a power calculation and determination
of effect size. Our study adds to this previous literature
as we specifically chose the inclusion of a comparator
group to allow for this statistical analysis. Second, in fur-
ther distinction to previous MeTree studies, we focused
on a sex-neutral primary outcome allowing us to explore
applicability to men and women patients alike. Third, we
are conducting this study in collaboration with devel-
opers of the software (co-investigators RW, ERH, and
LO), which facilitates informed conversations about risk
identification and incorporation into planned analyses.
Finally, as part of the shaping of the recruitment process,
we sought input from patient stakeholders. We met with
the Durham Center for Innovation to Accelerate Discov-
ery and Practice Transformation’s Veteran engagement
panel, who reviewed our recruitment materials and pro-
vided suggestions for tailoring study procedures to the
target population.
This study also has some limitations. First, the com-
parator arm will not receive risk assignment until 12
months after the immediate intervention arm. This
choice is justified by the ethical implications of not pro-
viding risk assessment results to patients. Fortunately,
the natural progression of CRC is slow and there is little
concern about this delay in overall individual patient
risk. Second, because randomization takes place at the
provider level, the potential patient pool is subject to
system-level changes and PCP turnover due to retire-
ment and/or new positions; however, this is expected to
be minimal. Finally, all patients enrolled in this study are
Veterans receiving care through the Department of Vet-
eran Affairs. While the VA patient population tends to
differ in important ways from the general United States
population (e.g. fewer women, more medical comorbidi-
ties), as a national, integrated system it is comparable to
other similarly structured healthcare systems [44].
Conclusion
Results from this trial will determine the effectiveness and
feasibility of incorporating patient-collected FHH and deci-
sion support on risk-identification and appropriate screening
of increased-risk individuals in a large healthcare system
such as the VA. Obtaining a detailed and accurate FHH is a
critical step in the identification of patients at increased risk
for certain cancers, including CRC. Unfortunately, FHH is
rarely obtained or documented in a consistent manner that
facilitates guideline-concordant, risk-appropriate care. This
study will contribute to the body of literature pursuing the
advancement of patient-centered, risk-appropriate care
provision and the ultimate goal of reducing the morbidity
and mortality of health conditions associated with genetic
predisposition.
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